Inflection Point Acquisition VI - Unit

Inflection Point Acquisition VI - Unit released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0, actual EPS USD -0.1886

Inflection Point Acquisition VI - Unit released FY2025 earnings on March 30 (EST), actual revenue USD 0, actual EPS USD -0.027

Inflection Point Acquisition VI - Unit released FY2026 Q3 earnings on December 23, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.0022

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

IPFXU

IPEX

IPEXR

IPCX

Inflection Point Acquisition Corp. VI has successfully completed an IPO, raising $253 million and a private placement of $7.4 million, with all proceeds placed in a trust account. The IPO consisted of 25.3 million units priced at $10 each, generating gross proceeds of $253 million. The private placement included 7.4 million warrants. As of March 30, 2026, the audited balance sheet shows total assets of $255.2 million and a shareholders' deficit of $10 million. Total transaction costs amounted to $17.3 million.

TradingView

Inflection Point  Acquisition

INFLECTION POINT ACQUISITION CORP V COM USD0.0001 CL A (SUB/RIGHST)

Inflection Point Acquisition Corp III

Inflection Point Acquisition Corp. VI raises $260.4M in IPO and private placement; $253M placed in trust

SBIO

CYTOF

BACQ

BACQU

The week of March 23rd, 2026, saw significant filing activity in the aerospace and healthcare sectors, despite no traditional IPOs. Three blank check companies, including Inflection Point Acquisition VI, raised a total of $220 million targeting technology-enabled businesses. Other notable filings included Alamar Biosciences and Kailera Therapeutics, each raising $100 million in the healthcare sector. Additionally, several SPACs, such as Collective Acquisition II and Oceanhawk Acquisition, also entered the pipeline with substantial funding plans.

RenaissanceCapital

ALPS Medical Breakthrough

ALTAMIRA THERAPEUTICS LTD

Aligos Therapeutics

iShares US Pharma

Galera Therapeutics

Kalaris Therapeutics

Inflection Point Acquisition IV

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

VG Health

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Karyopharm Therap

Bleichroeder Acquisition I - Unit

Ark Genomic Revolution ETF

MBX Biosciences

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

US Weekly Recap: Aerospace and healthcare issuers drive late-March filing activity

Inflection Point Acquisition Corp. VI has announced the pricing of its $220 million initial public offering (IPO) of 22 million units at $10.00 each, set to trade on Nasdaq under the ticker symbol "IPFXU" starting March 27, 2026. Each unit includes one Class A ordinary share and one-third of a redeemable warrant. The offering is expected to close on March 30, 2026, with Cantor Fitzgerald & Co. as the book-running manager. The company aims to pursue a business combination with North American or European businesses in disruptive growth sectors.

StockTitan

Inflection Point Acquisition Corp. VI Announces Pricing of $220 Million Initial Public Offering | IPFX Stock News

Inflection Point Acquisition VI - Unit(IPFXU.US)

Inflection Point Acquisition Corp. VI raises $260.4M in IPO and private placement; $253M placed in trust

US Weekly Recap: Aerospace and healthcare issuers drive late-March filing activity

Inflection Point Acquisition Corp. VI Announces Pricing of $220 Million Initial Public Offering | IPFX Stock News